Stockreport

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive N...

ImmunityBio, Inc.  (IBRX) 
PDF Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ Business Wire Thu, February 13, 2025 at 9:05 PM GMT+1 8 min read [Read more]